SCHEMBL20523698

SCHEMBL20523698

N#CC(=NNc1ccccc1)C(=O)c1cc(-c2ccccc2)on1

nearest known ligand 0.81

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
RAPGEF3 O95398 17/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20523740 0.87 RAPGEF3 (1.00) RAPGEF3
SCHEMBL20523686 0.83 RAPGEF3 (1.00) RAPGEF3
SCHEMBL22320772 0.83 RAPGEF3 (1.00) RAPGEF3
SCHEMBL20523727 0.83 RAPGEF3 (1.00) RAPGEF3
SCHEMBL15175065 0.81 RAPGEF3 (0.78) RAPGEF3
SCHEMBL15175066 0.81 RAPGEF3 (0.78) RAPGEF3
SCHEMBL20523712 0.81 RAPGEF3 (1.00) RAPGEF3
SCHEMBL23836620 0.80 RAPGEF3 (0.53) RAPGEF3
SCHEMBL20523754 0.79 RAPGEF3 (1.00) RAPGEF3
SCHEMBL20523644 0.79 RAPGEF3 (1.00) RAPGEF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11124489-B2 EPAC antagonists BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-09-21 US disclosed
US-20200255388-A1 EPAC ANTAGONISTS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-08-13 US disclosed
WO-2018183626-A1 EPAC ANTAGONISTS ZHOU JIA (US) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255388-A1 EPAC ANTAGONISTS EPAS1, GPR139, CRACR2A RAPGEF3 5/4885
US-11124489-B2 EPAC antagonists EPAS1, GPR139, CRACR2A RAPGEF3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.